200,000 adults with type 2 diabetes in South Korea found a 35% reduced dementia risk with SGLT-2 inhibitors compared to DPP-4 inhibitors.
A study in South Korea involving over 200,000 adults with type 2 diabetes found a 35% reduced risk of dementia for those taking SGLT-2 inhibitors, a common diabetes drug, compared to DPP-4 inhibitors, another diabetes medication. The study suggests that treatment with SGLT-2 drugs for longer durations could have more pronounced effects, with a 48% reduced risk of dementia for more than two years of treatment. However, randomized controlled trials are needed to confirm these findings.
August 28, 2024
31 Articles